A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00057395|
Recruitment Status : Unknown
Verified April 2004 by Aronex Pharmaceuticals.
Recruitment status was: Active, not recruiting
First Posted : April 2, 2003
Last Update Posted : June 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|Esophageal Neoplasms Hepatocellular Carcinoma Colorectal Neoplasms Ovarian Neoplasms Pancreatic Neoplasms Neoplasms||Drug: Aroplatin (Liposomal NDDP, L-NDDP)||Phase 1 Phase 2|
- Determine response rate (RR; complete and partial response [CR, PR]) and duration after therapy with Aroplatin™ in patients with advanced solid malignancies.
- Determine the safety and tolerability of Aroplatin
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00057395
|United States, California|
|John Wayne Cancer Institute|
|Santa Monica, California, United States, 90404|